Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Shelley Wood

November 09, 2016

News Daily News

New ‘Rapid Recommendations’ Tackle TAVR in Patients at Low-to-Intermediate Risk

Todd Neale

September 29, 2016

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Daily News

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Todd Neale

August 01, 2016

News Conference News TVT 2016

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

Michael O'Riordan

June 16, 2016

News Conference News EuroPCR 2016

Valvular Interventions for the Asymptomatic and Low Risk: Coming Soon to a Cath Lab Near You?

Yael L. Maxwell

May 20, 2016

News Daily News

Cardiac Surgery Risk Prediction with EuroSCORE Improved with Updated, Dynamic Modeling

Michael O'Riordan

March 01, 2016

News Daily News

MVARC Document Offers Template for Mitral Valve Therapeutics Research

Todd Neale

July 16, 2015

News Daily News

Survival Benefit of CoreValve in High-Risk Patients Persists at 2 Years

July 07, 2015

News Daily News

El Beneficio sobre la Supervivencia de CoreValve en Pacientes de Alto Riesgo se Mantiene a los 2 Años

July 07, 2015

News Daily News

CoreValve在高风险患者中的生存益处到2年时依然持续存在

July 07, 2015

News Daily News

Even With More Experience, Transapical TAVR Offers No Better QoL Than Surgery

Caitlin E. Cox

June 15, 2015

News Daily News

European TAVR Usage Tied to Economics, Reimbursement

Yael L. Maxwell

July 12, 2013

News Daily News

FDA, CMS Parallel Review Aims to Speed Access to Innovative Technologies

L.A. McKeown

October 14, 2011

News Conference News

PARTNER: TAVI Cost Effective Compared With Standard Care

Jason Kahn

April 03, 2011

Advertisement

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

New ‘Rapid Recommendations’ Tackle TAVR in Patients at Low-to-Intermediate Risk

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

Valvular Interventions for the Asymptomatic and Low Risk: Coming Soon to a Cath Lab Near You?

Cardiac Surgery Risk Prediction with EuroSCORE Improved with Updated, Dynamic Modeling

MVARC Document Offers Template for Mitral Valve Therapeutics Research

Survival Benefit of CoreValve in High-Risk Patients Persists at 2 Years

El Beneficio sobre la Supervivencia de CoreValve en Pacientes de Alto Riesgo se Mantiene a los 2 Años

CoreValve在高风险患者中的生存益处到2年时依然持续存在

Even With More Experience, Transapical TAVR Offers No Better QoL Than Surgery

European TAVR Usage Tied to Economics, Reimbursement

FDA, CMS Parallel Review Aims to Speed Access to Innovative Technologies

PARTNER: TAVI Cost Effective Compared With Standard Care

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content